"AIMS: To study whether morphologic (foveal thickness, FT) variations of clinical . significant macular oedema (CMO) in patients suffering from diabetes following. intravitreal pegaptanib sodium (IVP) injection were associated to functional. (macular sensitivity-MS- and color discrimination, CD) changes. METHODS: A. longitudinal, interventional, non randomized study was performed. FT was assessed. by optical coherence tomography (OCT); MS by microperimetry, best-corrected. visual acuity (BCVA) by early treatment diabetic retinopathy study charts (ETDRS). and CD by Farnswoth-Munsell test. Treatment protocol consisted of 3 consecutive. injections (0.3 mg\/ 0.05 ml; baseline, 6(th) week and 12(th) week). Follow-up. checks were scheduled at, 18-, 24-, 36- and 48-weeks, after injections. RESULTS: . Thirty eyes of 30 patients with clinically significant CMO were included for. analysis. After IVP a significant decrease of FT occurred with a mean reduction. from baseline of 56.9 % (p = 0.0001). An improvement of functional parameters was. recorded in all patients (BCVA from 18.2 ± 8.5 letters to 25.5 ± 8.4 letters, p< . 0.005; MS from 8.6 ± 2.16 dB to 10.6 ± 2.61 dB, p < 0.001; color analysis from. 376.1 ± 125.6 TES to 116 ± 34.6 TES, p = 0.0001). A statistically significant. correlation between FT and BCVA as well as MS and CD was also found. Neither. ocular nor systemic adverse events were reported. CONCLUSIONS: Intravitreal. pegaptanib significantly reduced FT, with a concomitant improvement of MS and CD.. This associations emphasizes the efficacy of IVP in the treatment of CMO. . . "
Intravitreal pegaptanib sodium (Macugen(®) ) for treatment of diabetic macular oedema: a morphologic and functional study
Chiosi, Flavia;DELL'OMO, Roberto;COSTAGLIOLA, Ciro
2012-01-01
Abstract
"AIMS: To study whether morphologic (foveal thickness, FT) variations of clinical . significant macular oedema (CMO) in patients suffering from diabetes following. intravitreal pegaptanib sodium (IVP) injection were associated to functional. (macular sensitivity-MS- and color discrimination, CD) changes. METHODS: A. longitudinal, interventional, non randomized study was performed. FT was assessed. by optical coherence tomography (OCT); MS by microperimetry, best-corrected. visual acuity (BCVA) by early treatment diabetic retinopathy study charts (ETDRS). and CD by Farnswoth-Munsell test. Treatment protocol consisted of 3 consecutive. injections (0.3 mg\/ 0.05 ml; baseline, 6(th) week and 12(th) week). Follow-up. checks were scheduled at, 18-, 24-, 36- and 48-weeks, after injections. RESULTS: . Thirty eyes of 30 patients with clinically significant CMO were included for. analysis. After IVP a significant decrease of FT occurred with a mean reduction. from baseline of 56.9 % (p = 0.0001). An improvement of functional parameters was. recorded in all patients (BCVA from 18.2 ± 8.5 letters to 25.5 ± 8.4 letters, p< . 0.005; MS from 8.6 ± 2.16 dB to 10.6 ± 2.61 dB, p < 0.001; color analysis from. 376.1 ± 125.6 TES to 116 ± 34.6 TES, p = 0.0001). A statistically significant. correlation between FT and BCVA as well as MS and CD was also found. Neither. ocular nor systemic adverse events were reported. CONCLUSIONS: Intravitreal. pegaptanib significantly reduced FT, with a concomitant improvement of MS and CD.. This associations emphasizes the efficacy of IVP in the treatment of CMO. . . "I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
